Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (281-290 of 356) with videos related to

Pageof 36
Sort By:
ERJ Open Research|July 28, 2020
Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?Christopher J Brereton, Timothy Wallis, Michelle Casey, et al.
Respiratory Research|May 21, 2022
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension studyGanesh Raghu, Mark J Hamblin, A Whitney Brown, et al.
The New England Journal of Medicine|October 14, 2011
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisLuca Richeldi, Ulrich Costabel, Moises Selman, et al.
The European Respiratory Journal|February 4, 2022
Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosisTim J M Wallis, Eyjólfur Gudmundsson, Katarina Pontoppidan, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 3, 2025
Air pollution and alveolar healthCarmelo Sofia, James G H Parkin, Joseph A Bell, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2009
Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup studyClaudia Jafari, Steven Thijsen, Giovanni Sotgiu, et al.
The Lancet. Respiratory Medicine|February 8, 2018
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?Paul J Wolters, Timothy S Blackwell, Oliver Eickelberg, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trialLuca Richeldi, Evans R Fernández Pérez, Ulrich Costabel, et al.
BMC Pulmonary Medicine|December 5, 2025
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)Wim A Wuyts, Luca Richeldi, Shervin Assassi, et al.
Pageof 36

Showing results (281-290 of 356) with videos related to

Sort By:
Pageof 36
ERJ Open Research|July 28, 2020
Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?Christopher J Brereton, Timothy Wallis, Michelle Casey, et al.
Respiratory Research|May 21, 2022
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension studyGanesh Raghu, Mark J Hamblin, A Whitney Brown, et al.
The New England Journal of Medicine|October 14, 2011
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisLuca Richeldi, Ulrich Costabel, Moises Selman, et al.
The European Respiratory Journal|February 4, 2022
Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosisTim J M Wallis, Eyjólfur Gudmundsson, Katarina Pontoppidan, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|September 3, 2025
Air pollution and alveolar healthCarmelo Sofia, James G H Parkin, Joseph A Bell, et al.
American Journal of Respiratory and Critical Care Medicine|July 11, 2009
Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup studyClaudia Jafari, Steven Thijsen, Giovanni Sotgiu, et al.
The Lancet. Respiratory Medicine|February 8, 2018
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?Paul J Wolters, Timothy S Blackwell, Oliver Eickelberg, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trialLuca Richeldi, Evans R Fernández Pérez, Ulrich Costabel, et al.
BMC Pulmonary Medicine|December 5, 2025
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)Wim A Wuyts, Luca Richeldi, Shervin Assassi, et al.
Pageof 36